Tango Therapeutics CEO to Participate in 2025 Cantor Global Healthcare Conference

Tango Therapeutics announced that CEO Barbara Weber will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 3. The live webcast will be available on the company's website, and a replay will be archived for 90 days. Tango Therapeutics is a clinical-stage biotech company focused on discovering novel drug targets and delivering precision medicine for cancer treatment using synthetic lethality.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for cancer treatment, has announced that Barbara Weber, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Wednesday, September 3, from 2:45 to 3:15 PM ET. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the company's website on the day of the event. A replay of the webcast will be archived on the company's website for 90 days following the presentation [1].

The fireside chat will provide investors and healthcare professionals with an opportunity to hear directly from Dr. Weber about Tango Therapeutics' ongoing research, clinical trials, and strategic initiatives. The company's approach to precision oncology leverages the genetic principle of synthetic lethality to discover and develop therapies that target critical cancer pathways [2].

Tango Therapeutics has made significant progress in its clinical programs, including first patient dosing in two trials: a combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors and a Phase 1/2 trial of TNG456 for glioblastoma. The company's collaboration with Gilead will conclude its research portion early, resulting in $53.8 million revenue recognition in Q3 2025 [3].

Investors can access the live webcast through the "Events & Presentations" section on the company's investor relations website. The presentation recording will remain available for 90 days following the event.

References:
[1] https://www.globenewswire.com/news-release/2025/08/26/3139116/0/en/Tango-Therapeutics-to-Participate-in-the-2025-Cantor-Global-Healthcare-Conference.html
[2] https://www.stocktitan.net/news/TNGX/tango-therapeutics-to-participate-in-the-2025-cantor-global-hmkg8bgwjj9p.html
[3] https://www.stocktitan.net/news/TNGX/